Key result
ECRAR overexpression quadruples cardiomyocyte proliferation and promotes post-MI functional recovery in rats.
Why the study?
Whether long non-coding RNAs can elicit a regenerative response in the post-natal heart remains unknown.
Does ECRAR overexpression promote cardiomyocyte proliferation and improve cardiac function in post-myocardial infarction models?
Does ECRAR overexpression promote cardiomyocyte proliferation and improve cardiac function in post-myocardial infarction models?
Absolute Event Rate: 22.7% vs 5.7%
p-value: p=<0.05
The identification of ECRAR as a driver of cardiomyocyte proliferation via ERK1/2 signaling provides a novel potential therapeutic target for cardiac regeneration after myocardial infarction.
Hypothesis-generating in rat MI models; extends lncRNA evidence for cardiomyocyte proliferation but clinical translation remains untested.
Reactivating post-natal myocardial regeneration potential may be a feasible strategy to regenerate the injured adult heart. Long non-coding RNAs (lncRNAs) have been implicated in regulating cellular differentiation, but whether they can elicit a regenerative response in the post-natal heart remains unknown. In this study, by characterizing the lncRNA transcriptome in human hearts during the fetal-to-adult transition, we found that 3,092 lncRNAs were differentially expressed, and we further identified a novel upregulated fetal lncRNA that we called endogenous cardiac regeneration-associated regulator (ECRAR), which promoted DNA synthesis, mitosis, and cytokinesis in post-natal day 7 and adult rat cardiomyocytes (CMs). Overexpression of ECRAR markedly stimulated myocardial regeneration and induced recovery of cardiac function after myocardial infarction (MI). Knockdown of ECRAR inhibited post-natal day 1 CM proliferation and prevented post-MI recovery. ECRAR was transcriptionally upregulated by E2F transcription factor 1 (E2F1). In addition, ECRAR directly bound to and promoted the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), resulting in downstream targets of cyclin D1 and cyclin E1 activation, which, in turn, activated E2F1. The E2F1-ECRAR-ERK1/2 signaling formed a positive feedback loop to drive cell cycle progression, and, therefore, it promoted CM proliferation. These findings indicated that our newly discovered ECRAR may be a valuable therapeutic target for heart failure.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) studied Myocardial infarction. ECRAR overexpression vs. Ad-null or AAV-null was evaluated on Cardiomyocyte proliferation (EdU incorporation in vitro) (p=<0.05). Overexpression of ECRAR increased cardiomyocyte proliferation from 5.7% to 22.7% in vitro and induced recovery of cardiac function after myocardial infarction in rat models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: